<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892047</url>
  </required_header>
  <id_info>
    <org_study_id>MH083660-01A1</org_study_id>
    <nct_id>NCT00892047</nct_id>
  </id_info>
  <brief_title>Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)</brief_title>
  <acronym>IRL GREY</acronym>
  <official_title>Incomplete Response in Late Life Depression: Getting to Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aims of this study are to:

        1. Assess the efficacy of aripiprazole augmentation for the acute and continuation
           treatment of TRLLD.

           Hypothesis 1: Patients with TRLLD (defined as those who do not remit after 12 weeks of
           acute treatment with venlafaxine XR) will have a higher rate of remission with
           aripiprazole than with placebo augmentation (primary outcome) and greater improvement in
           depressive symptoms and stability of remission (secondary outcomes).

        2. Assess the tolerability of aripiprazole in TRLLD with a focus on adiposity and
           akathisia/restlessness.

      Hypothesis 2: Aripiprazole will be associated with a higher rate of clinically significant
      akathisia and increased adiposity than placebo.

      The Secondary/exploratory aims of this study are to:

        1. Examine anxiety, medical burden, and executive impairment as moderators of aripiprazole
           augmentation efficacy in TRLLD.

           Hypothesis 3: Pre-levels of anxiety symptoms, medical burden, and executive impairment
           will be treatment-specific factors: they will moderate the efficacy of aripiprazole
           augmentation. The aripiprazole-placebo difference will be greater in individuals with
           these variables, compared to those without these variables because these three factors
           will be associated with a decreased likelihood that &quot;staying the course&quot; with
           venlafaxine monotherapy will achieve remission.

        2. Examine genetic predictors (phase 1) and moderators (phase 2-3) of treatment outcomes,
           while controlling for drug exposure.

      Hypothesis 4: Selected polymorphisms will reduce remission rate with venlafaxine and will
      reduce efficacy and tolerability with aripiprazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Incomplete response in the treatment of late-life depression (LLD) is a large public health
      challenge: at least 50% of older people fail to respond adequately to antidepressant
      pharmacotherapy, even under optimal treatment conditions. Treatment resistant late-life
      depression (TRLLD) increases risk for early relapse, undermines adherence to treatment for
      coexisting medical disorders, amplifies disability and cognitive impairment, imposes greater
      burden on family caregivers, and increases the risk for early mortality, including suicide.
      Getting to and sustaining remission is the primary goal of treatment, yet there is a paucity
      of controlled studies of how best to manage TRLLD.

      This is a multi-site study being conducted by 3 sites: University of Pittsburgh, University
      of Toronto, and Washington University. We propose to enroll 500 subjects aged 60 and older
      with major depressive disorder at this site and treat them openly for 12 weeks with
      venlafaxine XR (up to 300mg/d) (phase 1). Participants meeting criteria for incomplete
      response will be randomly assigned to receive either aripiprazole (2-15 mg/d; target dose: 10
      mg/d) or placebo augmentation (adding a pill without active medicine) of venlafaxine for 12
      weeks (phase 2), with the goal of achieving remission (MADRS≤10 for two consecutive
      assessments). Those who remit in phase 2 will receive continuation treatment, with the same
      double-blinded intervention to which they were randomly assigned (phase 3), for 12 weeks to
      determine the stability of remission. Efficacy and tolerability data will provide a
      clinically informative estimate of benefits and risks of aripiprazole augmentation for TRLLD.

      In addition to the primary goal of assessing these benefits and risks, we will develop
      evidence relevant to personalized treatment for LLD by testing the roles of clinical
      (comorbid anxiety, medical burden, and executive impairment) and genetic (selected
      polymorphisms in serotonin, norepinephrine, and dopamine genes) variables, while controlling
      for variability in drug exposure for efficacy and tolerability analyses. This approach will
      allow us to distinguish treatment-specific resistance factors versus general prognostic
      factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician rated ten item instrument assessing depression symptoms. Possible scores range from 0-60; higher scores indicate greater severity of depression. Remission defined as score of 10 or less based on the MADRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Akathisia</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants who developed clinically significant akathisia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline through12 weeks</time_frame>
    <description>Weight change in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parkinsonism</measure>
    <time_frame>12weeks</time_frame>
    <description>Percentage of participants who develop signs of parkinsonism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergent Suicidal Ideation in Those With no Ideation at the Start of Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>percentage of participants who reported suicidal ideation during treatment but not at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc Prolongation on EKG (to Greater or Equal to 480 Msec)</measure>
    <time_frame>12 weeks</time_frame>
    <description>percentage of participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1: venlafaxine plus aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo Comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine XR plus aripiprazole</intervention_name>
    <description>Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.</description>
    <arm_group_label>1: venlafaxine plus aripiprazole</arm_group_label>
    <other_name>effexor XR, abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine plus placebo</intervention_name>
    <description>Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.</description>
    <arm_group_label>2: Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 60 years.

          2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the SCID-IV.

          3. MADRS ≥ 15.

        Exclusion Criteria:

          1. Inability to provide informed consent.

          2. Depressive symptoms not severe enough (i.e., MADRS &lt; 15) at the baseline assessments.

          3. Dementia based upon DSM-IV criteria as well as a Folstein MMSE score of less than 24.
             Patients screened out due to dementia will be referred to a memory clinic or to the
             UPMC Alzheimer's Disease Research Center for evaluation to clarify the presence or
             absence of a dementia.

          4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms, as diagnosed by the SCID. A recommendation for psychiatric referral will be
             made in these cases.

          5. Abuse of or dependence on alcohol or other substances within the past 3 months as
             determined by SCID, and confirmed by study physician interview.

          6. High risk for suicide (e.g., active SI and/or current/recent intent or plan) AND
             unable to be managed safely in the clinical trial (e.g., unwilling to be
             hospitalized). Urgent psychiatric referral will be made in these cases.

          7. Contraindication to venlafaxine XR or aripiprazole as determined by study physician
             including history of intolerance of either venlafaxine XR or aripiprazole in the study
             target dosage range (venlafaxine XR at up to 225 mg/day; aripiprazole at up to
             15mg/day).

          8. Failure to respond to at least 6 weeks of venlafaxine (&gt;225 mg/d) plus aripiprazole
             (&gt;10 mg/d).

          9. Inability to communicate in English (i.e., interview cannot be conducted without an
             interpreter; subject largely unable to understand questions and cannot respond in
             English).

         10. Non-correctable clinically significant sensory impairment (i.e., cannot hear well
             enough to cooperate with interview)

         11. Unstable medical illness, including delirium, uncontrolled diabetes mellitus,
             hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that
             are not under medical management. This will be determined based on information from
             the patient's personal physician's and study physician clinical judgment. Referral to
             the patient's personal physician or to a general practitioner will be made in these
             cases.

         12. Subjects taking psychotropic medications that cannot be safely tapered or discontinued
             prior to study initiation: this would include patients on Monoamine Oxidase Inhibitors
             (MAOI) who would need to be off the MAOI for 14 days to be eligible for the study to
             avoid adverse drug interactions. Patients will not be allowed to take antidepressant
             or atypical antipsychotic medication other than the study medication, unless it is a
             low dose antidepressant prescribed for chronic pain that would not be medically
             advisable to stop (e.g., amitryptyline 50mg). If a patient's depression is adequately
             treated on his/her psychotropic medication, he/she would not be eligible for the
             study. If a patient failed a trial of venlafaxine (12 weeks of treatment with
             venlafaxine including at least 6 weeks on 300mg/day), he/she would not be eligible.
             The following are allowed: benzodiazepines up to 2mg/d lorazepam equivalent; other
             sedative-hypnotics (e.g., zolpidem, zaleplon, eszopiclone); gabapentin if prescribed
             for non-psychiatric indication (e.g., neuropathy). Except for MAOIs, there is really
             no clinical rationale to exclude patients on specific concomitant medications unless
             they are medically unstable (in which case they are excluded from participation). As
             noted, patients on an MAOI would need to be off the MAOI for 14 days to protect from
             adverse drug interactions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles F. Reynolds, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine, St. Louis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Mulsant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine, St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.latelifedepression.org</url>
    <description>An online resource for older individuals with emotional health problems</description>
  </link>
  <results_reference>
    <citation>Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Epub 2015 Sep 27. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.</citation>
    <PMID>26423182</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <results_first_submitted>December 16, 2015</results_first_submitted>
  <results_first_submitted_qc>December 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2015</results_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Charles Reynolds</investigator_full_name>
    <investigator_title>Director NIMH Center of Excellence in the Prevention and Treatment of Depression in Older Adults; UPMC Endowed Professor in Geriatric Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Venlafaxine</keyword>
  <keyword>Partial Remission</keyword>
  <keyword>Augmentation strategy</keyword>
  <keyword>Treatment resistance</keyword>
  <keyword>Elderly</keyword>
  <keyword>Late-life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 3 Centers (University of Pittsburgh, Centre for Addiction and Mental Health in Toronto, Canada, and Washington University). The first participant was enrolled July 2009, last finished August 2014.</recruitment_details>
      <pre_assignment_details>468 signed consent. 181 were randomized. Of these 181, 91 randomized to venlafaxine plus aripirazol and 90 to venlafaxine plus placebo. Prior to randomization, 191 responded to venlafaxine; 40 withdrew consent; 41 withdrawn by PI, possible AE, 14 non-compliance; 1 death.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1: Venlafaxine Plus Aripiprazole</title>
          <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>2: Placebo Comparator</title>
          <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject burden</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: Venlafaxine Plus Aripiprazole</title>
          <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>2: Placebo Comparator</title>
          <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" lower_limit="62.8" upper_limit="71.6"/>
                    <measurement group_id="B2" value="65.7" lower_limit="62.8" upper_limit="69.8"/>
                    <measurement group_id="B3" value="66.0" lower_limit="62.8" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician rated ten item instrument assessing depression symptoms. Possible scores range from 0-60; higher scores indicate greater severity of depression. Remission defined as score of 10 or less based on the MADRS.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Venlafaxine Plus Aripiprazole</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage of venlafaxine ranged from 150mg to 300mg. Dose of aripirpazole ranged from 2mg to 15mg. Subject remained on venlafaxine throughout the 36 week study. Subject remained on aripiprazole or placebo for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2: Placebo Comparator</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage of venlafaxine ranged from 150mg to 300mg. Dose of aripirpazole ranged from 2mg to 15mg. Subject remained on venlafaxine throughout the 36 week study. Subject remained on aripiprazole or placebo for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician rated ten item instrument assessing depression symptoms. Possible scores range from 0-60; higher scores indicate greater severity of depression. Remission defined as score of 10 or less based on the MADRS.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Akathisia</title>
        <description>Percentage of participants who developed clinically significant akathisia.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Venlafaxine Plus Aripiprazole</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2: Placebo Comparator</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Akathisia</title>
          <description>Percentage of participants who developed clinically significant akathisia.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weight</title>
        <description>Weight change in kilograms</description>
        <time_frame>Baseline through12 weeks</time_frame>
        <population>The number of participants analyzed is lower due to missing data attributable to dropouts. The information obtained is from figure 3B in the manuscript</population>
        <group_list>
          <group group_id="O1">
            <title>1: Venlafaxine Plus Aripiprazole</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2: Placebo Comparator</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>Weight change in kilograms</description>
          <population>The number of participants analyzed is lower due to missing data attributable to dropouts. The information obtained is from figure 3B in the manuscript</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="3.00"/>
                    <measurement group_id="O2" value="0.01" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parkinsonism</title>
        <description>Percentage of participants who develop signs of parkinsonism</description>
        <time_frame>12weeks</time_frame>
        <population>We have a lower number of participants analyzed due to dropouts and missed assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Venlafaxine Plus Aripiprazole</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2: Placebo Comparator</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinsonism</title>
          <description>Percentage of participants who develop signs of parkinsonism</description>
          <population>We have a lower number of participants analyzed due to dropouts and missed assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergent Suicidal Ideation in Those With no Ideation at the Start of Treatment</title>
        <description>percentage of participants who reported suicidal ideation during treatment but not at baseline</description>
        <time_frame>12 weeks</time_frame>
        <population>It is a smaller number of participants restricted to those who did not report any suicidal ideation at baseline. This is in Table 3of the manuscript</population>
        <group_list>
          <group group_id="O1">
            <title>1: Venlafaxine Plus Aripiprazole</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2: Placebo Comparator</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Emergent Suicidal Ideation in Those With no Ideation at the Start of Treatment</title>
          <description>percentage of participants who reported suicidal ideation during treatment but not at baseline</description>
          <population>It is a smaller number of participants restricted to those who did not report any suicidal ideation at baseline. This is in Table 3of the manuscript</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTc Prolongation on EKG (to Greater or Equal to 480 Msec)</title>
        <description>percentage of participants</description>
        <time_frame>12 weeks</time_frame>
        <population>We had a smaller number of participant observations due to dropouts and missing data. This data is in Table 3 of the manuscript.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Venlafaxine Plus Aripiprazole</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2: Placebo Comparator</title>
            <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>QTc Prolongation on EKG (to Greater or Equal to 480 Msec)</title>
          <description>percentage of participants</description>
          <population>We had a smaller number of participant observations due to dropouts and missing data. This data is in Table 3 of the manuscript.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1: Venlafaxine Plus Aripiprazole</title>
          <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine XR plus aripiprazole: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives aripiprazole 2mg to 15mg daily for up to 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>2: Placebo Comparator</title>
          <description>antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
venlafaxine plus placebo: Dosage varies. Subject remains on antidepressant throughout the 36 week study and also receives placebo for up to 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization for MI or CHF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diverticulitis or excessive vonmiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>limited number of participants older than 75, or members of racial/ethnic minority groups; limited follow-up period</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles F. Reynolds III, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-6414</phone>
      <email>reynoldscf@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

